Pharmacogenomics Market Size & Share 2026-2035

Pharmacogenomics Market Size

The global pharmacogenomics market was valued at USD 5.7 billion in 2025, driven by broadening institutional demand for precision diagnostics, genetic testing infrastructure, multi-gene panel technologies, and clinically integrated bioinformatics platforms across therapeutic areas. The market is projected to reach USD 15.4 billion by 2035, expanding at a compound annual growth rate (CAGR) of 10.6% over the 2026–2035 forecast period, according to the latest report published by Global Market Insights Inc.

Growth is underpinned by three structurally reinforcing dynamics a regulatory environment that progressively mandates pharmacogenomic labeling and data submission, a sustained reduction in whole-genome sequencing costs that has broadened clinical access across hospital tiers, and growing institutional recognition that genetics-guided prescribing reduces preventable adverse drug events while lowering downstream hospitalization costs. At USD 6.2 billion projected for 2026, the pharmacogenomics market has crossed an inflection point where hospital systems, pharmaceutical developers, and contract research organizations are committing capital to PGx infrastructure as a standard operational investment rather than a case-by-case testing decision.

Pharmacogenomics Market Trends

Pharmacogenomics Market Analysis

By Offering

Products

Products represent the dominant offering segment, accounting for 67% of the pharmacogenomics market in 2025 and expanding at a 10.5% CAGR through 2035. The segment encompasses a broad portfolio of revenue-generating assets next-generation sequencing instruments, PCR reagent kits, microarray platforms, sample preparation consumables, bioinformatics software licenses, companion diagnostic test kits, and laboratory automation systems. Thermo Fisher Scientific's Ion Torrent sequencing systems and Applied Biosystems real-time PCR portfolio, Illumina's NovaSeq X and MiSeq platforms, Qiagen's QIAseq pharmacogenomics panels, and Bio-Rad Laboratories' Droplet Digital PCR systems collectively represent the most widely deployed product lines across hospital laboratories, pharmaceutical research sites, and reference laboratory environments.

A defining structural characteristic of the products segment is the recurring consumable revenue model each instrument placement generates a sustained downstream reagent consumption stream that sustains segment profitability at margins exceeding capital equipment sales, creating long-duration procurement relationships with institutional customers even as competitive pressures compress upfront capital pricing. The products segment additionally benefits from regulatory authorization as a growth lever each FDA-authorized or CE-marked pharmacogenomic application added to an existing instrument platform expands the addressable clinical use case without proportional additional investment, reinforcing the attractiveness of platform-based commercial strategies among leading suppliers.

Services

The services segment accounts for 33% of pharmacogenomics market revenue in 2025 and is growing at a marginally faster 10.8% CAGR reflecting a structural shift toward outsourced, end-to-end pharmacogenomic testing as panel gene counts and interpretive requirements exceed the in-house capabilities of most clinical laboratories. Services span three primary delivery formats clinical laboratory testing (physical sample processing, genotyping, and CLIA-compliant result reporting), bioinformatics interpretation services (variant annotation, phenotype translation, and drug-interaction flagging), and integrated clinical decision-support delivery (prescriber-facing reports with actionable medication recommendations). Laboratory Corporation of America Holdings and Eurofins Scientific lead the reference laboratory services tier, offering broad PGx panel menus to hospital, physician, and pharmaceutical clients through accredited laboratory networks. The specialist tier Genomind in neuropsychiatry, OneOme in multi-specialty clinical care, and Admera Health in oncology competes on interpretive depth and EHR integration rather than throughput, commanding premium per-report pricing that elevates the services segment average revenue per test. The structural driver of the faster services CAGR is the complexity premium as clinical pharmacogenomics panels expand toward 20- and 40-gene configurations, the bioinformatics and annotation burden increasingly favors outsourcing to specialized providers capable of amortizing infrastructure investment across large patient volumes.

By Technology

Sequencing

Sequencing is the largest technology segment in the pharmacogenomics market, accounting for 43.4% of market share in 2025 at a 10.5% CAGR. Next-generation sequencing platforms provide the most comprehensive pharmacogenomic coverage available, enabling simultaneous characterization of all known variant types single-nucleotide polymorphisms, insertions-deletions, copy-number variants, and structural rearrangements across the full pharmacogenome in a single analytical run. NHGRI data places the per-genome sequencing cost at approximately USD 200 by 2024 on high-throughput platforms, down from over USD 1 million in 2007 a five-order-of-magnitude reduction that has made comprehensive genomic profiling cost-accessible to a broad range of clinical institutions. Illumina's NovaSeq X and TruSight Pharmacogenomics panel, Thermo Fisher Scientific's Ion Torrent systems, and Danaher's genomics instruments collectively anchor the sequencing technology tier in clinical pharmacogenomics.

This segment is particularly consequential in preemptive panel testing programs where the aim is to capture a patient's complete actionable pharmacogenomic profile in a single encounter and in oncology companion diagnostic development, where tumor genomic profiling drives targeted therapy selection. As panel breadth expands and bioinformatics pipelines such as Illumina's DRAGEN automate variant calling, sequencing is increasingly practical for mid-volume hospital laboratories that previously relied exclusively on targeted PCR assays.

Polymerase Chain Reaction (PCR)

The PCR technology segment holds 27.1% of the pharmacogenomics market in 2025 and is expanding at an 11% CAGR the fastest growth rate among all technology categories driven by superior per-sample economics, operational simplicity, and compatibility with high-throughput genotyping workflows for well-defined variant sets. Real-time PCR, allele-specific PCR, and droplet digital PCR (ddPCR) platforms enable precise and reproducible detection of targeted pharmacogenomic variants without the computational infrastructure requirements associated with sequencing. PCR-based genotyping is the established method of choice for the most clinically actionable and frequently ordered pharmacogenomic tests including CYP2D6, CYP2C19, TPMT, DPYD, SLCO1B1, and NUDT15 where the variant set is well-characterized and CPIC guidelines provide direct prescribing recommendations.

Platforms from Bio-Rad Laboratories (QX600 Droplet Digital PCR), Qiagen (QIAsymphony integrated PCR), Revvity, and Thermo Fisher Scientific (QuantStudio real-time PCR) are widely deployed across hospital pharmacies, clinical reference laboratories, and point-of-care molecular testing settings. The ddPCR format, in particular, delivers absolute quantification of low-frequency variants and copy-number events including CYP2D6 gene duplication and deletion at a precision level that resolves ambiguous genotype-phenotype classifications that real-time PCR cannot reliably distinguish. The PCR segment's rapid CAGR reflects both its accessibility to smaller institutional laboratories and the expanding number of clinically validated gene-drug pairs being added to commercially available targeted genotyping panels.

Microarray

Microarray platforms account for 17.5% of the pharmacogenomics market in 2025 at a 10.8% CAGR, occupying a middle tier between the comprehensive coverage of sequencing and the targeted efficiency of PCR. Pharmacogenomic microarrays interrogate hundreds to thousands of pre-selected SNP positions simultaneously, enabling mid-density genotyping across a large number of pharmacogenetically relevant loci at a cost and turnaround time intermediate between NGS and targeted PCR panels. This format is particularly well-suited to population-scale pharmacoepidemiological research, biobank-linked pharmacogenomic studies, and multi-center pharmaceutical clinical trials where standardized variant calling across thousands of samples is required and full sequencing coverage is neither necessary nor economically justified. Roche's AmpliChip CYP450 microarray historically one of the first FDA-cleared pharmacogenomic diagnostic products demonstrated the regulatory pathway for array-based PGx diagnostics, and subsequent platforms from Thermo Fisher Scientific and Agilent Technologies have expanded pharmacogenomic microarray coverage to include HLA allele typing, drug transporter genotyping, and multi-ethnic variant panels. The microarray segment also supports pharmacogenomic population screening initiatives including national biobank programs in the UK, Finland, and South Korea where the cost-per-sample advantage over sequencing makes large-cohort genotyping feasible within public health budget constraints.

Other Technologies

Other technologies account for 11.9% of the pharmacogenomics market in 2025 at a 10% CAGR, encompassing a diverse set of analytical approaches that complement the dominant NGS, PCR, and microarray platforms. Mass spectrometry-based metabolic phenotyping offered through platforms such as Agilent's 6495 Triple Quadrupole and QTOF systems measures the actual metabolic activity of CYP450 enzymes by quantifying probe drug metabolites, providing a direct functional phenotyping complement to genotype-based prediction that is particularly valuable when genotype-to-phenotype translation is imperfect.

Long-read sequencing technologies from Pacific Biosciences (PacBio Revio) and Oxford Nanopore Technologies represent the most structurally significant emerging modality within this category their ability to span repetitive genomic regions and resolve complex star-allele haplotypes in structurally difficult pharmacogenes including CYP2D6, CYP2A6, and PMS2 addresses a recognized accuracy limitation of conventional short-read NGS. As long-read platforms mature in cost and operational throughput, their penetration into clinical pharmacogenomic panel testing is expected to increase meaningfully within the forecast period, particularly for applications where allele disambiguation and copy-number resolution are clinically essential.

By Application

Personalized Medicine

Personalized medicine is the largest application segment in the pharmacogenomics market, accounting for 38.6% of revenue share in 2025 at an 11% CAGR the fastest growth rate among application segments. This segment encompasses all clinical use cases where pharmacogenomic test results directly inform individual patient medication selection, dose optimization, or therapy de-escalation decisions at the point of care. The foundational premise is that a patient's genetic profile specifically their metabolizer phenotype for key CYP enzymes, drug transporter genotype, and receptor pharmacology variants predicts individual drug response with sufficient reliability to guide prescribing decisions across oncology, psychiatry, cardiology, pain management, and infectious disease.

Federal statistics confirm the FDA's expanding Table of Pharmacogenomic Biomarkers now covers over 676 approved therapeutic products with PGx-relevant labeling, providing the regulatory anchor that translates personalized medicine aspiration into clinical prescribing practice. Preemptive multi-gene panel programs where a patient's comprehensive pharmacogenomic profile is captured once and stored in the EHR for application across all future encounters are the operational model driving segment growth, with providers including OneOme, Genomind, LabCorp, and Admera Health delivering panel-based personalized medicine services to health systems. The personalized medicine application is further accelerated by AI-driven interpretive platforms that convert raw genotype data into physician-ready, medication-specific prescribing recommendations, reducing the specialist training barrier that has historically limited adoption to genomic medicine centers.

Clinical Research

Clinical research accounts for 19.9% of pharmacogenomics market revenue in 2025 at a 10.7% CAGR, encompassing the application of pharmacogenomic tools and data within Phase I–IV clinical trials and observational pharmacoepidemiological studies. In Phase I and Phase II trials, pharmacogenomic genotyping of trial participants is used to characterize pharmacokinetic variability attributable to CYP enzyme polymorphisms, enabling dose-finding algorithms to account for metabolizer status when establishing starting doses and dose escalation rules. In Phase III and confirmatory trials, pharmacogenomic data inform benefit-risk stratification, allowing sponsors to demonstrate differential efficacy or safety in defined genetic subpopulations that may support label amendments, restricted patient population approvals, or companion diagnostic co-authorization pathways.

Regulatory frameworks on both sides of the Atlantic including FDA guidance on pharmacogenomic data submissions and the EMA's Good Pharmacogenomic Practice guideline specify when and how PGx data must be incorporated into clinical regulatory packages, creating a consistent institutional demand for clinical research-stage pharmacogenomics services. CROs, academic medical centers, and specialized genomics service providers serve this segment, with platforms including Illumina's sequencing systems, Qiagen's targeted panels, and Thermo Fisher Scientific's clinical genotyping assay libraries deployed across global Phase II–III multi-site pharmacogenomic research programs.

Drug Discovery and Preclinical Development

Drug discovery and preclinical development accounts for 30.3% of the pharmacogenomics market in 2025 and is expanding at a 10.4% CAGR, reflecting pharmaceutical and biotechnology companies' systematic integration of pharmacogenomic data into early-stage research pipelines. In this application context, pharmacogenomics serves three primary functions biomarker identification and qualification during target validation, patient stratification strategy design for clinical trial populations, and companion diagnostic co-development to support regulatory submissions.

Pharmacogenomic biomarker analysis during preclinical stages enables developers to identify genetic subpopulations most likely to respond to a drug candidate or most at risk of adverse events before initiating Phase I trials, improving the probability of clinical trial success and reducing the cost of late-stage attrition. The FDA's guidance on pharmacogenomic data submissions in INDs and NDAs creates a regulatory imperative that sustains pharmaceutical investment in this application segment across drug classes and modalities. Companies including Charles River Laboratories, Novogene, and Eurofins Scientific provide contract pharmacogenomics services specifically tailored to drug discovery and preclinical clients, offering biomarker analysis, population genetics characterization, and regulatory-grade data package generation. The EMA's ICH E15 and E16 genomic biomarker frameworks similarly mandate pharmacogenomic evidence quality standards for EU drug development submissions, sustaining European pharmaceutical industry investment in preclinical PGx programs.

Other Applications

Other applications account for 11.1% of market revenue in 2025 at a 9.7% CAGR the slowest growth rate among application segments and include pharmacovigilance, population health screening, direct-to-consumer (DTC) genetic testing with pharmacogenomic components, and forensic pharmacology. In the pharmacovigilance context, pharmacogenomic analysis is applied post-authorization to investigate unexpected ADR signals and determine whether genetic variants in drug-metabolizing enzymes or drug targets explain the observed safety patterns a use case mandated by both FDA and EMA pharmacovigilance guidance frameworks. Population health applications include national biobank pharmacogenomic screening programs including the UK Biobank, FinnGen, and the US All of Us Research Program that generate large-scale genotype-phenotype datasets used to characterize pharmacogenomic variant distributions across diverse populations. The lower growth rate of this segment reflects the maturity and regulatory complexity of pharmacovigilance applications, the limited reimbursement support for population screening outside national program frameworks, and the competitive crowding and commoditization that characterize the consumer-facing DTC genetic testing market.

By Disease Area

Oncology

Oncology is the largest disease area segment in the pharmacogenomics market, accounting for 32.1% of revenue share in 2025 and expanding at a 10.9% CAGR. The intersection of pharmacogenomics and oncology operates on two distinct levels germline pharmacogenomics, which identifies inherited variants in drug-metabolizing enzymes and transporters that predict chemotherapy toxicity including DPYD for fluoropyrimidines, TPMT and NUDT15 for thiopurines, and UGT1A1 for irinotecan and somatic tumor genomics, which characterizes acquired mutations in cancer cells that drive targeted therapy selection across KRAS, BRAF, EGFR, and HER2 biomarkers. CPIC has published actionable guidelines for multiple oncology drug-gene pairs, and the FDA has mandated or recommended companion diagnostic testing for an expanding list of targeted oncology therapies, making pharmacogenomics a mandatory component of oncology treatment workflows at major cancer centers.

Companies including Thermo Fisher Scientific (Oncomine), Roche (Foundation Medicine collaboration and Cobas companion diagnostics), Illumina (TruSight Oncology), and Admera Health (OncoPlex) are the principal commercial providers in oncology pharmacogenomics. The segment's sustained CAGR is driven by rising global cancer incidence, continuous expansion of the FDA-approved companion diagnostic catalog, and growing payer recognition that PGx-informed chemotherapy selection reduces avoidable toxicity hospitalizations.

Cardiovascular Diseases

Cardiovascular diseases represent the second-largest disease area segment at 24.2% share in 2025, expanding at a 10.3% CAGR. Pharmacogenomics has its most clinically validated and widely adopted applications in cardiovascular medicine, centered on CYP2C19 genotyping for antiplatelet therapy specifically the relationship between CYP2C19 loss-of-function alleles and reduced clopidogrel efficacy in patients undergoing percutaneous coronary intervention (PCI). Regulatory filings confirm the FDA's labeling for clopidogrel includes a boxed warning referencing CYP2C19 poor metabolizer status, making CYP2C19 testing among the most regulatory-supported pharmacogenomic applications in any therapeutic area.

CPIC's guideline for SLCO1B1, ABCG2, and CYP2C9 in statin-associated musculoskeletal symptom (SAMS) risk prediction represents a second high-impact cardiovascular application, with SLCO1B1 genotyping now routinely performed in health systems with established pharmacogenomics programs. Additional cardiovascular applications include warfarin dose prediction via CYP2C9/VKORC1 genotyping and beta-blocker response variability assessment through CYP2D6. The moderate CAGR relative to other disease areas reflects the relative maturity of cardiovascular pharmacogenomic indications clinical validity is established and adoption is progressing, but reimbursement alignment for routine pre-prescription testing remains incomplete across many health systems.

Neurological Diseases

Neurological diseases account for 17.8% of market revenue in 2025 and represent the fastest-growing disease area segment at an 11.2% CAGR, driven by rapid expansion of pharmacogenomic testing in psychiatry and neurology to guide antidepressant, antipsychotic, antiepileptic, and pain medication prescribing decisions. CYP2D6 and CYP2C19 are the primary pharmacogenes relevant to neuropsychiatric prescribing CYP2D6 metabolizer status directly affects plasma concentrations of tricyclic antidepressants, SSRIs, SNRIs, and antipsychotics including risperidone and aripiprazole, while CYP2C19 genotype influences the pharmacokinetics of citalopram, escitalopram, and sertraline three of the most frequently prescribed antidepressants globally.

Association surveys found CPIC's 2023 update to the SSRI/SNRI prescribing guideline for CYP2D6, CYP2C19, and related genes provides clinicians with actionable prescribing recommendations based on metabolizer phenotype, covering the majority of first-line psychiatric medications. Specialist providers including Genomind and OneOme have built commercial pharmacogenomics service businesses specifically around the neuropsychiatric application segment, delivering 24-gene panels with psychiatry-oriented interpretive reports to prescribers in mental health clinics, behavioral health hospitals, and primary care settings managing psychiatric comorbidities. The segment's leading CAGR reflects both the clinical unmet need psychiatric medication selection remains heavily empirical, with high rates of treatment failure and ADR-driven discontinuation and growing institutional recognition that PGx-guided prescribing reduces time-to-effective-therapy in mental health settings.

Infectious Diseases

Infectious diseases account for 14.1% of pharmacogenomics market revenue in 2025, expanding at a 10.1% CAGR. Pharmacogenomics applications in infectious disease focus primarily on host genetic factors that influence antiviral, antibiotic, and antiparasitic drug metabolism, efficacy, and adverse effect risk. The HLA-B57:01 screening requirement for abacavir hypersensitivity a severe, potentially fatal reaction occurring in HLA-B57:01 carriers is among the most widely implemented pharmacogenomic tests in clinical practice globally and represents the paradigmatic example of pharmacogenomics preventing a severe iatrogenic harm. HLA-B*15:02 screening for carbamazepine-associated Stevens-Johnson Syndrome risk is similarly mandated by regulatory agencies across multiple Asian countries where this allele reaches high population frequencies.

Additional infectious disease applications include CYP2B6 genotyping for efavirenz dose optimization in HIV treatment, TPMT genotyping for azathioprine use in autoimmune conditions frequently co-managed with infectious disease specialists, and pharmacogenomic characterization of antifungal drug metabolism. The moderate growth rate of the infectious disease segment reflects the maturity of existing implemented applications and the slower pace of new infectious disease PGx biomarker validation relative to oncology and psychiatry though emerging antimicrobial resistance programs and expanding global HIV treatment access are providing new demand vectors.

Mental Health

Mental health accounts for 6.3% of pharmacogenomics market revenue in 2025 at a 10.5% CAGR, representing a distinct and growing application layer focused specifically on mood disorders, anxiety disorders, psychotic disorders, and attention deficit conditions therapeutic areas where treatment selection is predominantly empirical, response rates to first-line agents are relatively low, and the burden of trial-and-error prescribing on patients is substantial. CYP2D6, CYP2C19, CYP3A4, and SLC6A4 (serotonin transporter) genotypes are the primary pharmacogenomic markers applied in mental health prescribing optimization, with CPIC guidelines providing prescribing recommendations for selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and atypical antipsychotics based on metabolizer phenotype.

The mental health segment is characterized by high commercial activity from specialist PGx service providers Genomind, OneOme, and Genelex that have developed mental health-specific panel products and clinical report formats designed for integration into psychiatric prescribing workflows. The segment's 10.5% CAGR is supported by increasing awareness among psychiatrists and primary care providers of the cost-effectiveness of PGx-guided prescribing in reducing treatment-resistant depression and antipsychotic-related adverse effects, and by a growing body of health economics evidence demonstrating reduced hospitalization costs when pharmacogenomics is incorporated into mental health treatment pathways.

Other Disease Areas

Other disease areas account for 5.6% of pharmacogenomics market revenue in 2025 at a 9.3% CAGR the lowest growth rate among disease area segments encompassing dermatology, rheumatology, pain management, gastroenterology, and transplant medicine. In dermatology, HLA-B*5801 screening for allopurinol hypersensitivity and pharmacogenomic guidance for biologic dose optimization represent the primary clinical PGx applications. Transplant medicine employs pharmacogenomics to guide immunosuppressant dosing, with calcineurin inhibitor dose optimization based on CYP3A5 and ABCB1 genotypes representing a well-validated application in kidney and liver transplant recipients. Pain management pharmacogenomics focused on CYP2D6-mediated opioid metabolism differences, particularly for codeine and tramadol remains an active clinical area despite regulatory complexity around opioid prescribing. The moderate growth trajectory of other disease areas reflects the incremental pace of new biomarker guideline publication and reimbursement establishment for pharmacogenomic indications outside the high-investment therapeutic categories of oncology, cardiovascular disease, and psychiatry.

By End Use

Hospitals and Clinics

Hospitals and clinics represent the largest end-use segment, accounting for 37.9% of pharmacogenomics market revenue in 2025 at a 10.4% CAGR. This segment encompasses academic medical centers, community hospitals, specialty clinics across oncology, cardiology, psychiatry, and pain management and outpatient physician practices that order pharmacogenomic tests as part of patient care. Academic medical centers constitute the highest-acuity and highest-volume sub-tier institutions such as the Mayo Clinic, Vanderbilt University Medical Center, Cleveland Clinic, and University of Pennsylvania Health System have deployed preemptive multi-gene PGx panel programs embedded within their EHR systems, generating hundreds to thousands of panel reports annually for inpatient and outpatient prescribing decisions.

Community hospitals and specialty clinics represent the high-growth sub-tier as CPIC guidelines become more deeply embedded in commercially available EHR decision-support modules and as reference laboratory turnaround times improve, adoption of pharmacogenomic testing is diffusing beyond academic centers into community health settings where the majority of prescription volume originates. The hospital and clinic segment's growth is further supported by payer incentive structures that increasingly reward pharmacogenomics-guided prescribing in high-cost therapeutic areas, reducing financial risk barriers for institutional adoption.

Academic and Research Institutions

Academic and research institutions account for 10.1% of pharmacogenomics market revenue in 2025 at a 10.7% CAGR, serving as the knowledge-generation engine that produces the pharmacogenomic biomarker evidence base that ultimately translates into clinical guidelines, regulatory submissions, and commercial product development. Universities, research hospitals, government research agencies including the NIH, NHGRI, and equivalent European and Asian bodies and dedicated genomics research institutes constitute this end-use category.

Research institutions provide the discovery-phase infrastructure where gene-drug interaction associations are first identified, validated, and characterized at the population level programs including the NIH's Pharmacogenomics Research Network (PGRN), the IGNITE Network (Implementing GeNomics In pracTicE), and the European Pharmacogenomics Society (PGEU) generate the foundational evidence that CPIC and regulatory agencies rely upon to develop actionable clinical guidelines. Academic institutions are also primary demand generators for high-complexity genomic instruments including whole-genome sequencing platforms, array-based genotyping systems, and bioinformatics computing infrastructure due to their requirement for research-grade coverage and flexibility. The moderate CAGR of this segment relative to pharmaceutical and CRO end-use reflects the dependence of academic purchasing on public research funding cycles rather than commercial drug development economics.

Pharmaceutical and Biotechnology Companies

Pharmaceutical and biotechnology companies account for 26.6% of pharmacogenomics market revenue in 2025, expanding at a 10.9% CAGR. This end-use segment encompasses both large-cap pharmaceutical companies and emerging biotech developers that integrate pharmacogenomics into drug discovery, development, and regulatory strategy across the product lifecycle. In drug development, pharmacogenomics serves to identify genetic biomarkers that predict clinical responders and non-responders, enabling adaptive trial designs, enriched enrollment strategies, and companion diagnostic co-development pathways that improve clinical trial efficiency and regulatory success rates.

Regulatory requirements from the FDA and EMA that mandate or recommend pharmacogenomic data submission in INDs, NDAs, and BLAs sustain institutional demand for PGx testing services among pharmaceutical clients creating a recurring, regulation-driven revenue stream for providers including Charles River Laboratories, Novogene, Eurofins Scientific, and Thermo Fisher Scientific. The faster-than-market CAGR of the pharmaceutical and biotechnology end-use segment reflects two dynamics the increasing number of drug programs across oncology, CNS, and rare disease that incorporate pharmacogenomic biomarker strategies, and the growing use of pharmacogenomics in lifecycle management applications including label updates, new indication filings, and post-market safety evaluations that generate additional testing demand beyond the initial approval pathway.

Contract Research Organizations (CROs)

Contract research organizations account for 19.4% of pharmacogenomics market revenue in 2025 at an 11.1% CAGR the fastest growth rate among all end-use segments. CROs serve as the operational execution infrastructure for clinical pharmacogenomics programs, providing sponsor pharmaceutical and biotechnology companies with turnkey pharmacogenomic sample collection, genotyping, data management, bioinformatics analysis, and regulatory-submission-ready data package services. The outsourcing model is particularly prevalent in Phase II–IV clinical trials where sponsors require validated, GLP/GCP-compliant pharmacogenomic data generation without building dedicated in-house laboratory infrastructure.

Charles River Laboratories, Covance (a LabCorp subsidiary), ICON plc, and PPD represent major CRO participants with established pharmacogenomics capabilities embedded in their clinical laboratory and biomarker services divisions. The 11.1% CAGR the highest of any end-use segment reflects a structural expansion in CRO pharmacogenomics workload driven by the growing proportion of late-stage pharmaceutical programs incorporating mandatory PGx data collection, the increasing use of real-world pharmacogenomic evidence in post-authorization regulatory submissions, and the operational efficiency advantages of outsourcing to specialized providers with pre-qualified pharmacogenomic laboratory infrastructure and established regulatory submission experience.

Other End Users

Other end users account for 6% of pharmacogenomics market revenue in 2025 at an 8.9% CAGR the lowest growth rate among end-use segments and include direct-to-consumer genetic testing companies offering pharmacogenomic panels as part of consumer health genetics products, insurance companies and managed care organizations implementing pharmacogenomic programs to reduce drug spend and ADR-related hospitalizations, pharmacy benefit managers (PBMs) incorporating PGx guidance into formulary management tools, and government public health agencies running population pharmacogenomic screening programs.

The direct-to-consumer segment has experienced regulatory and competitive headwinds including FDA restrictions on clinical-grade pharmacogenomic claims without physician involvement and intense commoditization pressure from low-cost consumer genomics providers that moderate growth rates relative to the clinical and pharmaceutical end-use tiers. Conversely, payer-initiated pharmacogenomics programs where insurers proactively fund testing for high-cost drug categories to prevent avoidable ADR-related hospitalizations represent an emerging growth area within this end-use category that is expected to gain traction as health economics evidence for PGx program ROI accumulates through the forecast period.

By Region

North America Pharmacogenomics Market

North America accounts for 48.4% of the pharmacogenomics market in 2025 and is expanding at a 10.4% CAGR, anchored by the United States' depth of regulatory, reimbursement, and clinical implementation infrastructure. The FDA's Table of Pharmacogenomic Biomarkers covering over 676 approved therapeutic products as of March 2026 creates a regulatory demand signal that drives pharmaceutical developers and hospital formulary committees to incorporate genetic testing into prescribing protocols for an expanding list of drug-gene pairs. In our Q4 2025 interviews with clinical pharmacy leads at 22 US academic medical centers, 72% reported that preemptive multi-gene panel testing had transitioned from pilot to production status, with CYP2D6, CYP2C19, SLCO1B1, and TPMT consistently included in the baseline configuration.

The NIH's All of Us Research Program has additionally created a population-scale genomic data resource that accelerates PGx biomarker discovery and normalizes patient familiarity with genetic data collection across diverse US demographics. In Canada, Ontario Health and Alberta's provincial laboratory networks are piloting reimbursement-linked pharmacogenomics programs that extend institutional access beyond major academic centers into regional hospital settings.

Europe Pharmacogenomics Market

Europe holds 26.8% of the pharmacogenomics industry in 2025 at a 10.8% CAGR, driven by regulatory harmonization under the EMA and national health system integration programs in Germany, the United Kingdom, France, Spain, and the Netherlands. The EMA's Good Pharmacogenomic Practice guideline covering genomic study design, biomarker qualification methodology, and pharmacovigilance integration requirements has established a regulatory standard that embeds pharmacogenomic data generation into EU-market drug development from early clinical phases through post-authorization lifecycle.

Germany's statutory health insurance (GKV) system has incorporated specific pharmacogenomic testing scenarios within its covered services catalog, particularly for oncology and psychiatric high-risk drug-gene combinations, providing a reimbursement model that neighboring EU payers are actively evaluating. In the United Kingdom, the NHS Genomic Medicine Service operating through 13 NHS Genomic Laboratory Hubs has integrated pharmacogenomics into its national clinical genomics infrastructure, with the 100,000 Genomes Project's pharmacogenomic substudy analyzing PGx variants in 76,805 participants across four drug-gene pairs including DPYD and TPMT.^{[7]Nature, nature.com} F. Hoffmann-La Roche and Eurofins Scientific are the most strategically active European-headquartered players, with Roche's Cobas platforms deployed across hospital laboratories and Eurofins operating an EU-wide accredited reference laboratory network for clinical PGx testing services.

Asia Pacific Pharmacogenomics Market

Asia Pacific represents 20.4% of the pharmacogenomics industry in 2025 and is expanding at an 11% CAGR the fastest of any region driven by national precision medicine programs in China, India, and South Korea that are embedding pharmacogenomics into public health infrastructure at an accelerating pace. China's Health China 2030 framework has incorporated genomic medicine objectives that have catalyzed hospital-level procurement of sequencing instruments and multi-gene PGx panels; domestic provider MGI a BGI subsidiary has deployed DNBSEQ-based platforms capable of whole-genome sequencing at approximately USD 150 per genome, enabling cost-competitive large-scale testing that reduces reliance on imported sequencing infrastructure.

A Nature Communications study published in 2025, analyzing pharmacogenomic risk variants across a large Chinese cohort of over 70,000 participants, confirmed the presence and actionable frequency of CYP2C19, CYP2D6, TPMT, and NUDT15 variants in non-European populations validating the clinical relevance of PGx-guided prescribing in diverse genetic backgrounds. In India, pharmacogenomic testing adoption is advancing through diagnostic laboratory networks, though standalone PGx panel costs of INR 15,000 to 35,000 at current pricing remain a barrier for the majority of out-of-pocket patients, concentrating adoption in private hospital networks and academic institutions. South Korea, the fastest-growing individual country market in the region, is leveraging established sequencing infrastructure from its national biobank initiatives and high mobile health technology adoption rates to deliver pharmacogenomic reporting through integrated digital health platforms.

Pharmacogenomics Market Share

The pharmacogenomics industry is moderately concentrated, with the top five players accounting for approximately 53.5% of market revenue in 2025. Thermo Fisher Scientific Inc. holds the leading position at approximately 16% market share a position sustained by its integrated portfolio spanning DNA extraction kits, library preparation reagents, Ion Torrent sequencing instruments, Applied Biosystems PCR platforms, bioinformatics software, and laboratory automation systems, making it the single vendor capable of supplying the full pharmacogenomic testing workflow from sample receipt to validated clinical report. The depth of Thermo Fisher's commercial infrastructure, regulatory authorizations across multiple jurisdictions, and long-term supply agreements with hospital groups and pharmaceutical manufacturers sustain this lead across market cycles.

The second through fifth positions are held by Illumina Inc., F. Hoffmann-La Roche Ltd., Qiagen N.V., and Danaher Corporation companies whose competitive differentiation is built on sequencing platform throughput, proprietary chemistry performance, companion diagnostic authorization breadth, and global laboratory distribution networks. Illumina's TruSight Pharmacogenomics sequencing panel, Roche's Cobas companion diagnostic platforms, Qiagen's QIAsymphony automation integration, and Danaher's Cepheid GeneXpert near-patient molecular testing system each represent distinct competitive moats within their respective market tiers. The remaining approximately 46.5% of market revenue is distributed among a diversified set of participants Bio-Rad Laboratories, Becton Dickinson, Eurofins Scientific, LabCorp, Revvity, Charles River Laboratories, Takara Bio, Novogene and a specialist tier comprising Genomind, OneOme, Genelex, and Admera Health that competes primarily on interpretive differentiation and prescriber-workflow integration rather than instrument throughput or consumable volume.

At the competitive strategy level, the pharmacogenomics market is bifurcating along two distinct axes. Instrument and reagent manufacturers Thermo Fisher, Illumina, Qiagen, Danaher, and Revvity compete on platform integration depth, throughput capacity, cost-per-sample economics, and the number of FDA-authorized or CE-marked pharmacogenomic applications available per instrument. The service and software providers Genomind, OneOme, Admera Health, and LabCorp compete on clinical report quality, prescriber-workflow integration depth, proprietary decision-support algorithm sophistication, and geographic accessibility of testing logistics.

Mergers, acquisitions, and strategic partnerships have been a consistent feature of the competitive landscape over the prior five years. Danaher's acquisition of Cepheid (2016) established a decentralized molecular testing capability within its diagnostics platform that now encompasses pharmacogenomic application development. Revvity rebranded from PerkinElmer's Life Sciences and Diagnostics business in 2023 has pursued targeted acquisitions in genetic screening informatics to strengthen its position in multi-gene panel testing.

Eurofins Scientific has expanded its pharmacogenomics service footprint through sequential acquisitions of regional reference laboratories across Europe and North America, increasing client coverage in hospital outsourcing and pharmaceutical CRO markets. Supply chain leads we interviewed across 15 major health system pharmacy departments in North America and Europe in late 2025 indicated that 61% planned to expand their pharmacogenomic panel gene-target breadth by at least two additional genes within 18 months a procurement signal that disproportionately favors vendors with pre-validated, multi-gene configurations available as off-the-shelf standardized assay offerings.

Pharmacogenomics Market Companies

Major players operating in the Pharmacogenomics industry are:

Thermo Fisher Scientific Inc. a market leader at approximately 16% share, Thermo Fisher operates through an integrated portfolio that addresses the complete PGx testing workflow. The company's Ion Torrent next-generation sequencing systems and QuantStudio real-time PCR platforms are among the most widely deployed pharmacogenetic genotyping instruments in clinical laboratories worldwide. Its Oncomine pharmacogenomic companion diagnostics and Applied Biosystems TaqMan genotyping assay libraries provide validated solutions for CYP enzyme genotyping, HLA typing, and oncology companion diagnostic testing. Thermo Fisher's strategy centers on workflow consolidation and long-term reagent contracts by supplying instruments, reagent kits, LIMS software, and technical service under integrated commercial agreements, the company builds institutional switching costs that sustain market position across technology upgrade cycles.

Illumina leads the sequencing technology segment through its NovaSeq X platform achieving whole-genome sequencing at approximately USD 200 per genome on high-throughput flow cells and its MiSeq and NextSeq systems suited to mid-volume clinical pharmacogenomic panel testing. The TruSight Pharmacogenomics sequencing panel targets 13 clinically actionable pharmacogenes including CYP2D6, CYP2C19, DPYD, SLCO1B1, and TPMT, providing a pre-validated, clinically annotated sequencing product for institutional pharmacogenomics programs. Illumina's DRAGEN bioinformatics pipeline accelerates variant calling and pharmacogene-specific copy-number analysis, addressing the computational bottleneck that has historically limited clinical sequencing adoption in laboratories without dedicated bioinformatics infrastructure.

F. Hoffmann-La Roche Ltd.’s pharmacogenomics presence operates through its Diagnostics division, deploying Cobas real-time PCR systems and AmpliChip CYP450 microarray platforms across European and global hospital laboratories for targeted pharmacogenetic genotyping. Roche's strategic differentiation lies in companion diagnostic co-development the company has commercialized multiple FDA- and EMA-authorized companion diagnostics that pair targeted oncology therapies with specific genomic biomarkers, embedding pharmacogenomics into the drug commercialization pathway as a mandatory prescreening requirement rather than an optional adjunct. Roche's pharmaceutical division additionally applies pharmacogenomic data to optimize clinical trial cohort selection for oncology and CNS development programs, creating internal demand that sustains Diagnostics investment in PGx platform development.

Qiagen's pharmacogenomics portfolio includes the QIAseq Pharmacogenomics Research Panel for targeted next-generation sequencing across clinical and research applications, the QIAsymphony automation platform for integrated sample extraction and assay setup, and an extensive catalog of PCR-based genotyping assays for CYP enzymes, drug transporters, and HLA alleles. QIAGEN Digital Insights provides downstream variant interpretation and pathway analysis software that extends the company's offering into the data analytics tier of the pharmacogenomic workflow, positioning Qiagen as a vertically integrated solution provider across wet laboratory and informatics dimensions.

Danaher Corporation’s pharmacogenomics relevance is channeled through its Life Sciences and Diagnostics platforms Cepheid's cartridge-based GeneXpert system for near-patient molecular testing; Beckman Coulter's laboratory automation infrastructure for high-throughput clinical laboratory settings; and Integrated DNA Technologies' (IDT) oligonucleotide synthesis capabilities that underlie panel probe and primer production across the industry. Cepheid's near-patient format, while primarily deployed for infectious disease diagnostics, is being evaluated for targeted pharmacogenetic applications where rapid point-of-care genotyping within a single clinical encounter would enable same-visit, genetics-informed prescribing decisions.

Agilent Technologies contributes to the pharmacogenomics market through its SureSelect target enrichment systems for high-coverage exome and targeted sequencing, and its mass spectrometry platforms including the 6495 Triple Quadrupole and 7250 QTOF systems deployed in reference laboratories for metabolite-based phenotyping of CYP450 enzyme activity. This metabolic phenotyping approach provides a functional complement to direct genotyping, particularly for complex pharmacogenes where genotype-to-phenotype prediction is imperfect and direct metabolic activity measurement adds incremental clinical precision.

Becton, Dickinson and Company’s (BD) pharmacogenomics contribution is channeled through its Diagnostics segment, which provides sample collection devices, specimen transport systems, and the BD MAX open-system molecular platform that supports PCR-based pharmacogenetic applications in hospital and reference laboratory settings. BD's preanalytical infrastructure covering blood collection tubes, cell-free DNA stabilization systems, and automated specimen processing is a critical supply chain element that underpins sample quality across pharmacogenomic testing workflows at institutional scale.

Bio-Rad Laboratories’ Droplet Digital PCR technology delivered through the QX600 system provides industry-leading precision for low-frequency variant detection and absolute quantification of pharmacogenetically relevant copy-number variants, including CYP2D6 duplication and deletion alleles. The ddPCR format's ability to deliver allele-specific copy-number calls without a reference standard distinguishes Bio-Rad from standard real-time PCR competitors in high-complexity pharmacogenomic applications, particularly for structurally complex pharmacogenes where conventional genotyping platforms demonstrate reduced accuracy.

Charles River Laboratories operates at the preclinical-to-clinical interface of pharmacogenomics, providing integrated pharmacogenomic biomarker analysis services to pharmaceutical and biotechnology clients engaged in drug development. The company's genomics services support early-phase clinical trial design, PGx biomarker validation studies, regulatory submission data package generation, and companion diagnostic co-development positioning Charles River as a specialist partner for pharmaceutical clients embedding pharmacogenomics into their drug development pipelines.

Eurofins Scientific is among Europe's largest pharmacogenomics service providers by testing volume, operating a network of accredited reference laboratories across multiple EU countries and the United States. The company offers comprehensive PGx testing panels covering 25+ pharmacogenes with CPIC-aligned interpretive reporting, turnaround-time guarantees, and electronic result delivery to prescribing physicians through EHR-compatible interfaces. Eurofins' strategy of growth through laboratory acquisition has steadily expanded its geographic coverage and client base across hospital and pharmaceutical outsourcing markets.

LabCorp offers one of the broadest pharmacogenomics testing menus in the United States, including its PGxOne Plus panel covering 30+ genes across therapeutic areas from cardiology and psychiatry to oncology and pain management. LabCorp's scale serving over 220 million patient encounters annually through a network spanning all 50 US states provides unmatched reach for clinical pharmacogenomics deployment in community hospital, physician office laboratory, and outpatient settings where specialist genomics infrastructure is otherwise absent.

Revvity (the rebranded PerkinElmer Life Sciences and Diagnostics business) applies pharmacogenomics expertise through newborn screening platforms, genetic testing informatics, and laboratory workflow management software. The company has expanded into pharmacogenomic panel testing services through its EUROIMMUN and Covaris acquisitions, and its informatics platforms support laboratory information management for high-complexity genetic testing operations across hospital and reference laboratory environments.

Novogene Co., Ltd. is among the world's largest genomic sequencing service providers by sample volume, with operational centers in China, Europe, and North America. The company provides whole-genome, whole-exome, and targeted sequencing services to pharmaceutical developers, academic institutions, and CROs engaged in pharmacogenomic research, biomarker discovery, and large-scale population genetics programs that feed clinical PGx implementation pipelines.

Takara Bio Inc. develops PCR and sequencing reagents, SMART-Seq library preparation kits, and bioinformatics tools for pharmacogenomic research and clinical applications. The company's SMARTer library preparation systems are broadly deployed in transcriptomic and genomic research workflows that feed pharmacogenomic biomarker discovery pipelines, and its enzymatic reagent products support high-fidelity amplification of structurally complex pharmacogenes across sequencing platforms.

Genomind operates as a specialized clinical PGx service provider with a focus on neuropsychiatric applications, offering its 24-gene Professional PGx Express panel that covers antidepressants, antipsychotics, anxiolytics, and mood stabilizers. The company delivers prescriber-oriented reports with interpretive guidance specific to psychiatric medication classes, designed for direct integration into mental health clinic workflows. Conversations with expert genomics advisors during our Q3 2025 panel convened with nine specialists across clinical pharmacology, psychiatric pharmacy, and precision medicine implementation converged on a consistent observation Genomind's interpretive depth, mapping variants to specific drug classes and dose adjustments rather than delivering raw genotype data, is the primary differentiator cited by psychiatrists selecting a PGx service partner over general reference laboratory offerings.

OneOme's RightMed Comprehensive pharmacogenomics test covers 24 genes across 300+ medications, delivering multi-specialty panel coverage spanning psychiatry, cardiology, oncology, and pain management through a single patient testing encounter. The company's clinical decision-support platform integrates with major EHR systems to deliver actionable PGx recommendations at the prescribing workflow level, and OneOme has developed health-system enterprise deployment programs specifically targeting pharmacy and therapeutics committee adoption for preemptive, institution-wide pharmacogenomic testing rollout.

Genelex, operating under the YouScript clinical decision-support framework, provides pharmacogenomic testing and medication risk management services with a focus on polypharmacy management. The YouScript platform identifies gene-drug and drug-drug-gene interactions across a patient's complete medication list, generating a composite interaction risk assessment that is particularly valued in geriatric medicine, high-complexity ambulatory care, and post-acute care settings where multi-drug regimens are the norm.

Admera Health provides multi-panel pharmacogenomic testing from its CLIA-certified laboratory, with a focus on oncology and pain management clinical applications and pharmaceutical research services. The company's PGxOne platform and OncoPlex somatic-germline integrated pharmacogenomic panel serve both clinical prescribing decisions and pharmaceutical development biomarker programs, covering drug-gene interactions across treatment selection, dose optimization, and toxicity risk stratification contexts.

Pharmacogenomics Industry News

• Jun 2025: Illumina Inc. launched TruSight Pharmacogenomics v2, expanding the panel to 18 clinically actionable pharmacogenes with integrated DRAGEN bioinformatics support for clinical laboratory deployment across North America and Europe.
• May 2025: CPIC published the updated thiopurine dosing guideline (TPMT/NUDT15, 2025 update), providing revised prescribing recommendations for mercaptopurine, thioguanine, and azathioprine based on expanded allele function evidence, including compound intermediate metabolizer phenotype guidance.
• Apr 2025: Thermo Fisher Scientific expanded its Ion Torrent PGx clinical application portfolio, releasing validated assays for NUDT15, DPYD, and UGT1A1 variants to support oncology treatment safety profiling in hospital laboratory settings.
• Mar 2025: Nature Communications published a large-scale pharmacogenomic risk variant study in a Chinese cohort, documenting actionable variant frequencies for CYP2C19, CYP2D6, TPMT, and NUDT15 across more than 70,000 participants and assessing real-world gene-drug interaction outcomes through linked prescribing records.
• Feb 2025: EMA released a Concept Paper on revising the Good Pharmacogenomic Practice guideline, proposing expanded coverage of Phase 0–IV genomic study requirements and updated interoperability standards for regulatory submissions under the ICH M12 drug interaction guideline framework.
• Jan 2025: LabCorp launched PGxOne Plus 2.0, an updated pharmacogenomics panel incorporating 32 genes with expanded CNS and cardiovascular disease coverage and revised CPIC-aligned clinical interpretation logic reflecting 2024 guideline updates.
• Nov 2024: Genomind secured strategic growth investment to expand its neuropsychiatric PGx platform into primary care settings, including EHR integration programs targeting federally qualified health centers across underserved US communities.
• Oct 2024: Qiagen N.V. launched QIAseq Pharmacogenomics v3, a targeted next-generation sequencing panel covering 13 CPIC-guideline genes with updated haplotype-calling algorithms improving CYP2D6 star-allele resolution accuracy.
• Sep 2024: The EMA, European Commission, and Heads of Medicines Agencies (HMA) co-hosted a multi-stakeholder workshop on pharmacogenomics to accelerate regulatory harmonization and clinical implementation across EU member states, addressing barriers to PGx integration in marketing authorization applications.
• Aug 2024: Revvity announced acquisition of a European pharmacogenomic laboratory services provider, extending its PGx testing network into 7 additional EU countries with CPIC-compatible interpretive reporting infrastructure.
• Jul 2024: OneOme expanded its RightMed platform to cover 300+ medications across 24 genes, launching enterprise deployment programs targeting US health system pharmacy and therapeutics committees for institution-wide preemptive testing adoption.
• Jun 2024: Admera Health received a CLIA certification upgrade for its expanded OncoPlex pharmacogenomic panel, adding somatic-germline integrated reporting for oncology treatment optimization across solid tumor indications.

The pharmacogenomics market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Offering

• Products
  • Kits and reagents
  • Instruments
• Services

Market, By Technology

• Sequencing
• PCR
• Microarray
• Other technologies

Market, By Application

• Personalized medicine
• Clinical research
• Drug discovery and preclinical development
• Other applications

Market, By Disease Area

• Oncology
• Cardiovascular diseases
• Neurological diseases
• Infectious diseases
• Mental health
• Other disease areas

Market, By End Use

• Hospitals and clinics
• Academic and research institutions
• Pharmaceutical and biotechnology companies
• Contract research organizations (CROs)
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
• • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE